PCOM2 - The Physician Communication Intervention, Version 2.0 (NCT05336240)
PCOM2 - The Physician Communication Intervention, Version 2.0" for "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake"
🩺 Plain-English Summary (8th-Grade Level)
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, was found to be effective for increasing adolescent HPV vaccination in primary care, its dissemination is limited by the need for significant research team involvement to teach providers how to use the intervention's components. To address this, investigators propose to develop and test a virtual version of PCOM, use mixed methods to assess contextual factors affecting its use compared to the original PCOM intervention, and develop an optimized version of PCOM for broad dissemination to increase adolescent HPV vaccination nationally.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (3 items).
Location: University of Colorado Anschutz Medical Campus — Aurora, Colorado
Age range: 9 Years to 17 Years
🧪 Interventions in This Study
- Physician Communication 2 Virtual (PCOM2-virtual) (BEHAVIORAL)
- Physician Communication Standard (PCOM-standard) (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Parents: Does not have an adolescent between the ages of 9-17 years old and is not receiving adolescent care at an enrolled clinic
- Providers: Providers who are not at participating study practices
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- University of Kansas Medical Center — Wichita, Kansas
📞 Contact the Study Coordinator
Phone: (303) 724-0906
Email: CHRISTINE.BABBEL@CUANSCHUTZ.EDU
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HPV Infection
- Feasibility of HPV Testing With Mail-delivered Sample Collection Kits — San Francisco, California
- Intradermal, Fractional Dose of HPV Vaccines: — Seattle, Washington
- Immunogenicity of Fractional Dose of the HPV Vaccines — Seattle, Washington
- Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer — New Haven, Connecticut
- An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen — Boston, Massachusetts
Explore by condition: All HPV Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.